Table 1 Baseline patient characteristics
Variables | Study populations | |||||
|---|---|---|---|---|---|---|
Total (n = 566) | CEA/CA 19-9 analysed (n = 545) | CA 19-9 detected (n = 494) | CA 19-9 not detected (n = 51) | CEA analysed RAS/BRAF analysed (n= 440) | CA 19-9 detected RAS/BRAF analysed (n = 399) | |
Age (years) | ||||||
Median (min, max) | 62 (24, 75) | 62 (24, 75) | 62 (24, 75) | 60 (30, 75) | 62 (24, 75) | 62 (24, 75) |
Gender, n (%) | ||||||
Male | 334 (59) | 322 (59) | 292 (59) | 30 (59) | 265 (60) | 241 (60) |
Female | 232 (41) | 223 (41) | 202 (41) | 21 (41) | 175 (40) | 158 (40) |
WHO performance status, n (%) | ||||||
0 | 380 (67) | 367 (67) | 328 (66) | 39 (76) | 295 (67) | 263 (67) |
1 | 162 (29) | 155 (28) | 145 (29) | 10 (20) | 126 (29) | 119 (29) |
2 | 24 (4) | 23 (4) | 21 (4) | 2 (4) | 19 (4) | 17 (4) |
Location primary tumour, n (%) | ||||||
Colon | 333 (59) | 321 (59) | 297 (60) | 24 (47) | 265 (60) | 244 (61) |
Rectum | 233 (41) | 224 (41) | 197 (40) | 27 (53) | 175 (40) | 155 (39) |
Previous surgery, n (%) | ||||||
Primary tumour resected | 382 (67) | 369 (68) | 334 (68) | 35 (69) | 335 (76) | 303 (76) |
Intact primary tumour | 184 (33) | 176 (32) | 160 (32) | 16 (31) | 105 (24) | 96 (24) |
Prior pelvic RT, n (%) | ||||||
Yes | 80 (14) | 75 (14) | 68 (14) | 7 (14) | 66 (15) | 60 (15) |
No | 486 (86) | 470 (86) | 426 (86) | 44 (86) | 374 (85) | 339 (85) |
Prior adjuvant CT, n (%) | ||||||
Yes | 51 (9) | 49 (9) | 42 (9) | 7 (14) | 44 (10) | 38 (10) |
No | 515 (91) | 496 (91) | 452 (91) | 44 (86) | 396 (90) | 351 (90) |
Time of metastases, n (%) | ||||||
Synchronous | 402 (71) | 389 (71) | 347 (70) | 42 (82) | 298 (68) | 266 (67) |
Metachronous | 164 (29) | 156 (29) | 147 (30) | 9 (18) | 142 (32) | 133 (33) |
Number of metastatic sites, n (%) | ||||||
1 site | 162 (29) | 155 (28) | 137 (28) | 18 (35) | 130 (30) | 115 (29) |
>1 sites | 404 (71) | 390 (72) | 357 (72) | 33 (65) | 310 (70) | 284 (71) |
Alkaline phophatase level, n (%) | ||||||
Normal | 298 (53) | 286 (52) | 258 (48) | 26 (55) | 240 (55) | 217 (54) |
>UNL | 268 (47) | 259 (48) | 236 (48) | 23 (45) | 200 (45) | 182 (46) |
Platelet count, n (%) | ||||||
≤400/nL | 398 (70) | 383 (70) | 347 (70) | 36 (71) | 315 (72) | 287 (72) |
>400/nL | 168 (30) | 162 (30) | 147 (30) | 15 (29) | 125 (28) | 112 (28) |
White blood cell count, n (%) | ||||||
≤10/nL | 428 (76) | 416 (76) | 369 (75) | 44 (86) | 345 (78) | 309 (77) |
>10/nL | 138 (24) | 132 (24) | 125 (25) | 7 (14) | 95 (22) | 90 (23) |
RAS/BRAF mutation status, n (%) | ||||||
RAS/BRAF wild-type | 15a (37) | 186 (42) | 171 (43) | |||
RAS mutation | 22a (54) | 201 (46) | 179 (45) | |||
BRAF mutation | 4a (10) | 53 (12) | 49 (12) | |||
CRP level, n (%) | ||||||
≤10 mg/L | 18b (45) | 194d (45) | 176f (45) | |||
>10 mg/L | 22b (55) | 234d (55) | 212f (55) | |||
IL-6 level, n (%) | ||||||
<5.6 ng/L | 21c (54) | 193e (49) | 172g (49) | |||
≥5.6 ng/L | 18c (46) | 199e (51) | 181g (51) | |||
